![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/f42cf5e88e95cf3ad2098e209fd9cf1ea8f9c5d8-1920x1080.png?fit=crop&auto=format)
Solid Biosciences Tracking Long-Term Effects of Duchenne Muscular Dystrophy Gene Therapy in Phase 1/2 IGNITE-DMD Study
Solid Biosciences’ SGT-001, an investigational adeno-associated virus (AAV) vector-based gene therapy for Duchenne muscular dystrophy (DMD), is currently being evaluated in the phase 1/2 IGNITE-DMD clinical trial (NCT03368742).1,2 Following up on World …